Alkermes plc reported $1.67B of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.67B (to Q2 2026). Net income: $66M, trailing twelve months to Q2 2026. Free cash flow: $222M, trailing twelve months to Q2 2026. Operating margin: 7.3%, trailing twelve months to Q2 2026.

ALKSAlkermes plc

Healthcare

$40.63+46% 1Y

$40.63

$27.1352 weeks$52.99

ALKS as reported

Alkermes plc reported $1.67B of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed.

$1.67B

Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before

Net income: $66M
Net income · −81% year on year · trailing twelve months to Q2 2026
Free cash flow: $222M
Free cash flow · −54% year on year · trailing twelve months to Q2 2026
Operating margin: 7.3%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ALKS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.67B	+11%	Q2 2026
Net income	$66M	−81%	Q2 2026
EPS	$0.38	−82%	Q2 2026
Gross margin	85%	n/a	Q2 2026
Operating margin	7.3%	n/a	Q2 2026
Net margin	4.3%	n/a	Q2 2026
ROE	11%	n/a	Q2 2026
ROA	7.3%	n/a	Q2 2026
ROIC	41%	n/a	Q3 2024 · 7 quarters behind
Free cash flow	$222M	−54%	Q2 2026
P/E	107	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.